A randomized factorial trial of reperfusion strategies and aspirin dosing in acute myocardial infarction

This publication has 16 references indexed in Scilit:

• A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: The Duke University clinical cardiology study (DUCCS) 1
  Journal of the American College of Cardiology, 1994
• Anistreplase versus alteplase in acute myocardial infarction: Comparative effects on left ventricular function, morbidity and 1-day coronary artery patency
  Journal of the American College of Cardiology, 1992
• Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: Results of the rt-PA-APSAC patency study (TAPS)
  Journal of the American College of Cardiology, 1992
• ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarction
  Published by Elsevier ,1992
• Comparative effects of APSAC and rt-PA on infarct size and left ventricular function in acute myocardial infarction. A multicenter randomized study.
  Circulation, 1991
• Optimal utilization of thrombolytic therapy for acute myocardial infarction: Concepts and controversies
  Journal of the American College of Cardiology, 1990
• In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin
  The Lancet, 1990
• The Thrombolysis in Myocardial Infarction (TIMI) Trial
  New England Journal of Medicine, 1985
• Value of partial ejection fraction, volume increment, and regional wall motion in identifying patients with clinically significant coronary artery disease.
  Circulation, 1983
• Variability in the measurement of regional left ventricular wall motion from contrast angiograms.
  Circulation, 1983